Orchid Pharma Ltd
Orchid Pharma Ltd (ORCHPHARMA) last reported results for the quarter ended Jun 2026, with sales of ₹304 crore and net profit of ₹3.22 crore. The stock last traded at ₹973, a market capitalisation of ₹5,829 crore, on a P/E of 323. Over the past 52 weeks the stock has ranged between ₹471 and ₹1,144. Figures are as of 6 Oct 2026 and are not real time.
Orchid Pharma Ltd share price and key metrics
- Current price
- ₹973
- Market cap
- ₹5,829 cr
- Stock P/E
- 323
- Book value
- ₹300
- ROE
- 1.49%
- ROCE
- 1.86%
- Dividend yield
- 0.00%
- 52w high / low
- 1144/471
Metrics as of 6 Oct 2026. Not real time.
Track Orchid Pharma Ltd
Cruxal reads every Orchid Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Orchid Pharma Ltd growth and returns
- 10 Years
- 4%
- 5 Years
- 22%
- 3 Years
- 23%
- TTM
- 14%
- 10 Years
- 8%
- 5 Years
- 17%
- 3 Years
- 53%
- TTM
- -72%
- 10 Years
- 38%
- 5 Years
- 18%
- 3 Years
- 22%
- 1 Year
- 30%
- 10 Years
- %
- 5 Years
- 5%
- 3 Years
- 7%
- Last Year
- 1%
Orchid Pharma Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹304 cr, up 15.6% from ₹263 cr a year earlier. Net profit turned positive at ₹3.22 cr.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 223 | 217 | 237 | 263 | 194 | 207 | 368 | 304 |
| Expenses | 192 | 191 | 209 | 269 | 195 | 206 | 338 | 290 |
| Operating profit | 30.34 | 26.37 | 27.99 | -5.65 | -1.47 | 1.56 | 30.16 | 14 |
| OPM % | 13.62% | 12.13% | 11.79% | -2.15% | -0.76% | 0.75% | 8.19% | 4.60% |
| Other income | 7.52 | 8.49 | 3.9 | 11.57 | 10.77 | -1.5 | 7.55 | 1.83 |
| Interest | 3.33 | 3.8 | 3.92 | 2.28 | 3.73 | 3.18 | 1.96 | 2.23 |
| Depreciation | 8.63 | 8.61 | 8.87 | 10.53 | 8.9 | 9.03 | 10.9 | 10.95 |
| Profit before tax | 25.9 | 22.45 | 19.1 | -6.89 | -3.33 | -12.15 | 24.85 | 2.65 |
| Tax % | 0.00% | 0.00% | -0.21% | 0.00% | 0.00% | 0.00% | 0.00% | 2.64% |
| Net profit | 27.24 | 20.78 | 22.29 | -5.69 | -5.72 | -12.61 | 25.84 | 3.22 |
| EPS (₹) | 5.37 | 4.10 | 4.39 | -1.12 | -1.13 | -2.49 | 5.09 | 0.63 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Orchid Pharma Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 797 | 683 | 600 | 484 | 450 | 560 | 666 | 819 | 1,398 | 1,233 | 1,073 |
| Operating profit | 3 | 24 | -12 | -31 | 29 | 55 | 84 | 111 | 151 | 48 | 44 |
| OPM % | 0.4% | 3.6% | -2.0% | -6% | 7% | 10% | 13% | 14% | 11% | 3.9% | 4.1% |
| Net profit | -495 | -353 | 69 | -131 | -117 | -2 | 46 | 92 | 135 | 10 | 11 |
| EPS (₹) | -55.69 | -39.65 | 7.80 | -32.11 | -28.55 | -0.48 | 11.35 | 18.17 | 26.63 | 1.96 | 2.10 |
TTM is the trailing twelve months to the most recent quarter.
Orchid Pharma Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 89 | 89 | 89 | 41 | 41 | 41 | 41 | 51 | 15 | 15 |
| Reserves | -556 | -881 | -793 | 725 | 612 | 607 | 648 | 1,119 | 1,494 | 1,504 |
| Borrowings | 3,106 | 3,202 | 3,230 | 566 | 453 | 268 | 331 | 135 | 154 | 307 |
| Other liabilities | 616 | 715 | 551 | 128 | 132 | 195 | 205 | 249 | 414 | 432 |
| Total liabilities | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 2,077 | 2,258 |
| Fixed assets | 1,497 | 1,386 | 1,256 | 858 | 670 | 584 | 573 | 620 | 708 | 692 |
| CWIP | 288 | 272 | 278 | 26 | 7 | 10 | 46 | 31 | 81 | 414 |
| Investments | 1 | 1 | 0 | 0 | 15 | 45 | 44 | 46 | 60 | 67 |
| Other assets | 1,470 | 1,467 | 1,542 | 576 | 544 | 472 | 561 | 857 | 1,229 | 1,086 |
| Total assets | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 2,077 | 2,258 |
As reported by the company. Total assets equal total liabilities by construction.
Orchid Pharma Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 401 | 9 | 12 | 81 | 24 | 92 | 18 | 126 | 51 | 126 |
| Cash from investing | -176 | -28 | 45 | 167 | 67 | 113 | -31 | -312 | -36 | -277 |
| Cash from financing | -465 | 33 | -0 | -250 | -165 | -217 | 31 | 167 | 2 | 137 |
| Net cash flow | -240 | 15 | 57 | -2 | -74 | -11 | 18 | -19 | 17 | -14 |
| Free cash flow | 392 | 3 | 5 | 77 | 23 | 238 | -8 | 61 | -102 | -255 |
| CFO / operating profit | 13,628% | 67% | -138% | -226% | 63% | 173% | 22% | 113% | 44% | 259% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Orchid Pharma Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | -4% | -4% | -5% | -6% | -5% | -2% | 5% | 9% | 9% | 2% |
| Debtor days | 75 | 64 | 73 | 51 | 110 | 111 | 118 | 87 | 92 | 113 |
| Inventory days | 196 | 202 | 214 | 254 | 244 | 201 | 217 | 199 | 187 | 161 |
| Days payable | 402 | 374 | 381 | 182 | 176 | 195 | 165 | 173 | 137 | 150 |
| Cash conversion cycle | -130 | -108 | -94 | 123 | 179 | 117 | 170 | 113 | 142 | 124 |
| Working capital days | -500 | -876 | -1,158 | 166 | 302 | 97 | 54 | 118 | 101 | 105 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Orchid Pharma Ltd shareholding pattern
Promoters held 74.45% at Sep 2026, up from 69.84% at Sep 2025. FIIs 0.92% and DIIs 17.54%.
| % held | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 74.45% |
| FIIs | 2.53% | 2.69% | 1.39% | 1.56% | 1.17% | 0.87% | 0.80% | 0.92% |
| DIIs | 19.00% | 20.10% | 19.43% | 19.04% | 19.38% | 20.24% | 20.75% | 17.54% |
| Public | 8.63% | 7.37% | 9.34% | 9.57% | 9.61% | 9.04% | 8.62% | 7.08% |
| No. of shareholders | 34,158 | 34,303 | 39,827 | 38,155 | 35,709 | 35,118 | 33,433 | 33,260 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Orchid Pharma Ltd corporate filings
- Certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulation, 2018Company Updatelow impact
- Corporate AGM results indicate strong shareholder approval for key resolutions, including financial statements, director reappointment, and related party transactions, with high voting margins. The approval of related party transactions and director reappointment suggests continuity in management and strategic direction. The detailed voting data shows over 99% approval for most resolutions, reflecting robust investor confidence. This positive shareholder sentiment could reinforce market perception of stability and support near-term stock price stability or modest uptick, especially given the company's small-cap status and recent financial disclosures.AGM/EGMmedium impact
Cruxal's analysis: The company, Orchid Pharma Limited, reported overwhelmingly positive voting outcomes at…
Read the full analysis - No financial or strategic update; regulatory filing pertains to AGM proceedings of Orchid Pharma Limited on September 29, 2026AGM/EGMlow impact
Cruxal's analysis: This regulatory filing details the proceedings of Orchid Pharma Limited's 33rd AGM held…
Read the full analysis - Intimation of Trading Window closure for Quarter-II of Financial Year 2026-27, ending on September 30, 2026.Insider Trading / SASTlow impact
- Orchid Pharma Limited receives trading approval for 4.46 crore equity shares issued under NCLT-sanctioned amalgamationCompany Updatelow impact
Cruxal's analysis: Orchid Pharma Limited has received formal trading approval from the NSE and BSE for 4…
Read the full analysis - Orchid Pharma Ltd files routine regulatory intimation under SEBI LODRCompany Updatelow impact
Cruxal's analysis: Orchid Pharma Ltd has submitted a routine regulatory filing under Regulation 30 of the…
Read the full analysis - Orchid Pharma schedules investor roadshow in MumbaiCompany Updatelow impact
Cruxal's analysis: Orchid Pharma has announced an investor roadshow to be held in Mumbai. This engagement…
Read the full analysis - Orchid Pharma Ltd releases Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Orchid Pharma Ltd has filed its Annual Report for the financial year 2025-26. The…
Read the full analysis - Orchid Pharma Ltd files Business Responsibility and Sustainability Report (BRSR) for FY 2025-26Otherslow impact
Cruxal's analysis: Orchid Pharma has submitted its Business Responsibility and Sustainability Report (BRSR)…
Read the full analysis - Orchid Pharma Limited Announces 33rd AGM and Seeks Shareholder Approval for Material Related Party Transactions and Director AppointmentsAGM/EGMmedium impact
Cruxal's analysis: Orchid Pharma Limited has scheduled its 33rd Annual General Meeting for September 29…
Read the full analysis - Orchid Pharma Limited Announces Board Changes and Schedules 33rd Annual General MeetingOtherslow impact
Cruxal's analysis: Orchid Pharma Limited has announced the appointment of Mr. Arjun Dhanuka as a Whole-Time…
Read the full analysis - Orchid Pharma Q1 FY27 Earnings Call: Strategic Focus on 7-ACA Backward Integration and Global Exblifep ExpansionCompany Updatemedium impact
Cruxal's analysis: Orchid Pharma Limited reported Q1 FY27 revenue of INR 304 crore, reflecting 15% YoY…
Read the full analysis - Orchid Pharma releases audio recording of Q1 FY2027 earnings callCompany Updatelow impact
Cruxal's analysis: Orchid Pharma has filed the audio recording of its analyst/investor earnings call held…
Read the full analysis - Orchid Pharma Reports Q1 FY27 Turnaround with Consolidated PAT of 3.22 crore Following Strategic AmalgamationCompany Updatehigh impact
Cruxal's analysis: Orchid Pharma Limited has released its Q1 FY27 investor presentation, highlighting a…
Read the full analysis - Orchid Pharma Ltd schedules Q1 FY2027 earnings callCompany Updatelow impact
Cruxal's analysis: Orchid Pharma Ltd has announced an investor and analyst earnings call to discuss the…
Read the full analysis - Orchid Pharma files statement of deviation or variation for QIP proceeds for quarter ended June 30, 2026Company Updatelow impact
Cruxal's analysis: Orchid Pharma has submitted its mandatory statement regarding the deviation or variation…
Read the full analysis - Orchid Pharma Ltd files Monitoring Agency Report for Q1 FY 2026-27Company Updatelow impact
Cruxal's analysis: Orchid Pharma has submitted its Monitoring Agency Report for the first quarter of the…
Read the full analysis - Orchid Pharma Limited Files Revised Audited Financial Results for FY26 Following Amalgamation of Dhanuka LaboratoriesCompany Updatelow impact
Cruxal's analysis: Orchid Pharma Limited has released revised standalone and consolidated financial results…
Read the full analysis - Orchid Pharma Reports Q1 FY27 Financial Results Amidst Amalgamation and Strategic Global ExpansionResultmedium impact
Cruxal's analysis: Orchid Pharma Limited reported Q1 FY27 consolidated net sales of 304.17 crore and a net…
Read the full analysis - Orchid Pharma schedules Board Meeting for August 14, 2026, to approve Q1 FY27 results and restated FY26 financialsBoard Meetinglow impact
Cruxal's analysis: Orchid Pharma Limited has announced a board meeting scheduled for August 14, 2026, to…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.